As featured in
Testosterone has a reputation problem where hair is concerned — blamed for baldness by gym folklore, feared by women prescribed it for menopause, watched anxiously by trans men starting masculinising therapy, and misunderstood almost everywhere. The truth is more precise and more useful: testosterone doesn’t destroy hair. Its by-product DHT does — and only in follicles genetically programmed to care. Understand that one sentence properly and every testosterone-and-hair question becomes answerable.
This page covers the mechanism once, then applies it to the people actually asking: women with high androgens, women prescribed testosterone, trans men on masculinising therapy, and anyone told their hairline means their hormones are “too high”.
The mechanism, once and properly
In scalp skin, the enzyme 5-alpha-reductase converts a fraction of circulating testosterone into dihydrotestosterone — DHT — several times more potent at the androgen receptor. In follicles carrying genetic sensitivity, DHT progressively shrinks the growth apparatus: each cycle produces a shorter, finer hair until the follicle effectively retires. That’s pattern hair loss, entire. Two corollaries do most of the explanatory work. First, sensitivity beats level: perfectly normal testosterone thins sensitive follicles, while sky-high testosterone leaves resistant ones alone — which is why the “bald men have more testosterone” folklore fails, and why blood results alone never settle the question. Second, the pattern is the signature: androgen-driven loss shows at temples, crown and parting in predictable geography, which an examination reads directly off the scalp.
Women, androgens and thinning hair
Women run the same machinery at lower volume — and hair-wise, what matters is the balance. PCOS raises androgen production against normal oestrogen; menopause drops oestrogen against continuing androgens; either way the androgen share rises and susceptible follicles respond with the widening parting of female pattern loss — sometimes with facial hair arriving on the same shift. Increasingly relevant: testosterone prescribed to women, most often for libido and energy in menopause care. Used at physiological female doses with monitoring it’s legitimate medicine — and in women with follicle sensitivity it can still nudge pattern thinning along, which is a reason for baseline photographs and hair-aware monitoring, not a reason to refuse the therapy. The blood work that reads all of this — testosterone, SHBG and the free androgen index, interpreted for hair rather than against generic ranges — is exactly what our panel does.
| Who’s asking | What’s usually happening | What helps |
|---|---|---|
| Woman with widening parting + irregular cycles | PCOS-pattern androgen excess | Bloods + scalp exam; anti-androgen treatment (see PMOS/PCOS clinic) |
| Woman thinning through menopause | Oestrogen fall shifting the androgen balance | Menopause clinic; HRT review where relevant |
| Woman prescribed testosterone, worried | Possible pattern-loss nudge in the susceptible | Baseline photos + monitoring; treat early if change appears |
| Trans man on masculinising therapy | DHT revealing genetic susceptibility | Dedicated trans men’s page: goals-aware treatment |
| Anyone told ‘your testosterone is too high’ by a hairline | Folklore: sensitivity beats level | An actual examination and actual bloods |
Treating androgen-driven loss — at the follicle, not the folklore
Because the problem lives where DHT meets the follicle, that’s where treatment works. Blocking the conversion: finasteride and dutasteride reduce DHT production — first-line in men, used selectively and off-label in women, and a nuanced goals-based decision in trans men. Blocking the receptor: spironolactone blunts androgen signalling at the follicle — a mainstay for women with androgen-driven thinning. Bypassing hormones entirely: minoxidil, topical or low-dose oral, stimulates growth regardless of the androgen picture and pairs with everything above. What rarely helps: crashing your testosterone. Within normal and therapeutic ranges, susceptible follicles answer to DHT’s presence more than its precise quantity — so the productive lever is almost never “lower the hormone” and almost always “protect the follicle”, which conveniently leaves the testosterone doing whatever legitimate job it was prescribed or produced for.
Two groups worth a closer look: PCOS, and women prescribed testosterone
PCOS deserves its own paragraph because it’s the commonest androgen-excess story we see, and hair is often its most distressing symptom: the free androgen index rises (more androgen production, often less SHBG to bind it), susceptible follicles at the parting respond, and facial hair frequently arrives on the same tide. The treatment logic follows the mechanism — anti-androgens like spironolactone at the follicle, combined hormonal contraception where it suits, metformin and metabolic work at the root — and responds well when it’s actually diagnosed, which is why unexplained pattern thinning plus irregular cycles should always trigger the blood panel. Women prescribed testosterone — a fast-growing group in menopause care — sit at the opposite, gentler end: physiological doses, real quality-of-life benefits, and a small hair risk concentrated in those with genetic susceptibility. The management isn’t avoidance but bookkeeping: a baseline photo set when starting, a look at the scalp at review, and early follicle-protective treatment in the minority who need it. Both groups illustrate the page’s one law: manage the follicle’s exposure, not the hormone’s headline number.
What patients say
She let me cry, listened to my history and made me feel understood and heard. She checked my scalp … and gave me an action plan to fight my hair loss. I'm 35 and been through scary surgery and hormonal changes and she gave me hope back.
One of the most helpful parts was piecing together all of my health issues and blood tests to review how they all interact … I've come away with a solid action plan.
Getting your actual answer
The internet answers testosterone-and-hair questions with folklore because it can’t examine your scalp. A consultation can: trichoscopy reads whether your loss carries the androgen signature, bloods read for hair establish your real hormonal picture, and the plan follows the findings — the right blocker, the right support, baseline photographs, review dates. Fifty minutes with Dr Amy replaces months of forum anxiety with a diagnosis. Unsure it’s worth it? Message the clinic on WhatsApp and we will tell you straight.
Not directly, and the distinction matters. Hair loss follows DHT, testosterone’s more potent by-product, and only in follicles genetically sensitive to it. Someone with modest testosterone and sensitive follicles loses hair; someone with high testosterone and resistant follicles keeps a full head. So a receding hairline is evidence about your follicle genetics, not your testosterone level, and ‘high testosterone’ found on a blood test doesn’t doom your hair any more than normal results protect it. Pattern, examined under magnification, tells the real story.
No: this is the most durable myth in hair. Studies consistently show bald and non-bald men with comparable testosterone levels; what differs is follicle sensitivity to DHT, which is genetic. The myth survives because it flatters, but it misleads in both directions: it shames men losing hair and falsely reassures those keeping it about their hormones. If you want to know your androgen status, that’s a blood test; if you want to know why your hair is thinning, that’s an examination.
Usually not: at the physiological doses used in women’s menopause care, most women notice no scalp change at all. The exception is women carrying follicle sensitivity (family history of pattern thinning is the clue), where added testosterone can nudge a widening parting along. The sensible approach isn’t refusing helpful therapy: it’s baseline photographs when you start, hair-aware monitoring, and early treatment (spironolactone, finasteride, minoxidil) if change appears. Managed that way, the therapy and your hair can almost always coexist.
Because level was never the deciding factor. In women, thinning usually follows the androgen balance (testosterone relative to oestrogen and to SHBG, the protein that binds it), so menopause’s oestrogen fall or PMOS’s production rise can drive pattern thinning with ‘normal’ testosterone on the printout. And in anyone, sensitive follicles respond to ordinary DHT levels. This is why the useful blood work is testosterone with SHBG and the free androgen index, read for hair, and why the scalp examination, which sees the androgen pattern directly, outranks any single number.
It’s almost never the right lever. Within normal and therapeutic ranges, susceptible follicles respond to DHT’s presence rather than its precise quantity, so suppressing testosterone trades real costs (energy, mood, muscle, libido, or the purpose it was prescribed for) for little scalp benefit. Effective treatment works at the follicle instead: blocking conversion to DHT (finasteride/dutasteride, where appropriate), blocking the receptor (spironolactone in women), or bypassing hormones entirely (minoxidil). Protect the follicle; leave the testosterone to its job.
Substantially, when caught while follicles are miniaturised rather than lost. Blockers and minoxidil regrow measurable hair in most people who start early, and progression can be halted at any stage, which protects everything still growing. Follicles that spent years shrinking to nothing don’t return with medication; established bald areas are transplant territory. The pattern across every version of this condition is identical: the arithmetic rewards early action, which is why ‘baseline now, monitor, treat at first change’ beats waiting to be sure.
